Axon Enterprise (NASDAQ:AXON) Given New $700.00 Price Target at The Goldman Sachs Group

Axon Enterprise (NASDAQ:AXON) had its price objective raised by The Goldman Sachs Group from $500.00 to $700.00 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

AXON has been the topic of several other research reports. JMP Securities boosted their price target on shares of Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a research report on Thursday, October 31st. Robert W. Baird boosted their target price on shares of Axon Enterprise from $600.00 to $800.00 and gave the company an “outperform” rating in a report on Friday, December 6th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. TD Cowen began coverage on Axon Enterprise in a report on Wednesday, January 8th. They issued a “buy” rating and a $700.00 price objective on the stock. Finally, Northland Securities raised their target price on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $524.85.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $604.68 on Monday. The business’s 50 day moving average price is $617.75 and its 200 day moving average price is $474.21. The company has a market cap of $46.11 billion, a price-to-earnings ratio of 156.25, a PEG ratio of 6.09 and a beta of 1.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise has a one year low of $247.04 and a one year high of $698.67.

Insider Transactions at Axon Enterprise

In other news, Director Caitlin Elizabeth Kalinowski sold 450 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. This represents a 6.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jeffrey C. Kunins sold 21,834 shares of Axon Enterprise stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $593.88, for a total value of $12,966,775.92. Following the completion of the transaction, the insider now owns 154,394 shares of the company’s stock, valued at approximately $91,691,508.72. This trade represents a 12.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,545 shares of company stock valued at $30,721,337. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Axon Enterprise

Large investors have recently made changes to their positions in the company. Public Sector Pension Investment Board lifted its holdings in Axon Enterprise by 19.2% during the 3rd quarter. Public Sector Pension Investment Board now owns 3,104 shares of the biotechnology company’s stock worth $1,240,000 after buying an additional 500 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Axon Enterprise by 9.2% during the 3rd quarter. CIBC Asset Management Inc now owns 10,578 shares of the biotechnology company’s stock worth $4,227,000 after acquiring an additional 895 shares in the last quarter. Foundations Investment Advisors LLC purchased a new stake in Axon Enterprise during the third quarter worth approximately $221,000. Sequoia Financial Advisors LLC boosted its holdings in Axon Enterprise by 4.9% in the third quarter. Sequoia Financial Advisors LLC now owns 1,727 shares of the biotechnology company’s stock valued at $690,000 after purchasing an additional 81 shares in the last quarter. Finally, Axxcess Wealth Management LLC purchased a new position in Axon Enterprise in the third quarter valued at approximately $814,000. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.